EN DE
Watch Medline Inc. Class A Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medline Inc. Class A (MDLN) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Medline Inc. Class A stock $28.64, price $39.76, that is 28.0% below the price, quality 50 out of 100. Rating: overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MI Medline Inc. Class A logo Some data Nov 5, 2026

Medline Inc. Class A

MDLN · US
Overvalued / Monitor

Our calculation puts a fair price 28% below what the stock costs today.

Healthy Growth (revenue 3y +9.9 %/yr in USD)
Generates free cash flow
Quality 50/100
Thin margins · 2.3% net margin (TTM)
Moderate debt
Insiders bought $170,750 (6M) · sold $3.7M
Some data
Costs 92 times its yearly profit.
Fair value $28.64 · Overvalued (−28.0%)
Trails peers (2/12)
Narrow moat 33/100 · thin data
Negative coverage

Risks from the AI analysis

🚩Rivals like McKesson or Cardinal Health🚩FDA oversight failures and recalls
Watch Medline Inc. Class A Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$49.99 $31.64 Fair Value $28.64 Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

11‑month range $31.64 – $49.99 · fair‑value band $15.89 – $36.33 · the $39.76 price screens above the $28.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Medline Inc. Class A Common Stock in your weekly email

Every Wednesday you see whether Medline Inc. Class A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.

Show moreShow less

The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics.

Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products.

Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants.

Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products.

It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers.

It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.

Stock analysis

Medline Inc. Class A (MDLN) currently trades at $39.76, while our model-based Fair Value estimate is $28.64, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $29.06 per share, and 1 of the 22 models we run sit above the $39.76 price.

Bear case: the Economic Profit group reads lowest at $12.29, and 21 of the 22 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $15.89 (bear) to $36.33 (bull), the price of $39.76 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Medline Inc. Class A Common Stock reported revenue of $28.4B in FY2025 versus $21.4B in FY2022, a compound +9.9%/yr. Reported net income was $1.2B in FY2025.

Key figures

Market cap $54.3B Large · P/E ratio 91.7 · P/S ratio 1.18 · EPS (TTM) $0.4400 · Net margin 2.3% · Return on equity 4.9% · Return on assets (EBIT) 5.3% · Operating margin 0.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

For context, the median of 10 Healthcare peers we cover trades at −57% fair-value upside, at −28%, MDLN screens cheaper than that median.

Fair Value models

Bear $15.89 Fair Value $28.64 Bull $36.33
Price $39.76 · Downside -28.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3737 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $9.13 $12.56 $15.55 73
FCF DCF $15.91 $35.65 $67.99 72
Growth DCF $15.89 $34.43 $64.14 71
All 22 models by family
DCF Models
FCF DCF $15.91 $35.65 $67.99 72
Owner Earnings $6.76 $20.04 $41.79 67
5Y Revenue Exit $12.22 $28.64 $50.37 66
5Y EBITDA Exit $18.47 $41.12 $68.89 69
5Y P/E Exit $10.54 $25.27 $41.51 65
10Y Revenue Exit $12.51 $28.21 $51.12 60
10Y EBITDA Exit $17.30 $37.11 $66.01 62
10Y P/E Exit $12.16 $25.81 $43.99 59
Earnings-Based
Graham-Dodd $8.98 $37.30 $50.85 61
Lynch FV $9.42 $13.46 $17.50 58
PEG = 1.0 $9.42 $13.46 $17.50 55
EPV $9.13 $12.56 $15.55 73
Multiples
P/E Multiple $21.80 $29.06 $36.33 63
P/S Multiple $16.84 $22.46 $28.07 58
EV/EBIT $20.04 $30.75 $41.47 65
EV/EBITDA $22.79 $34.42 $46.06 66
EV/Revenue $10.84 $20.67 $30.50 52
Growth DCF
Growth DCF $15.89 $34.43 $64.14 71
Rev-Margin DCF $12.22 $28.42 $48.64 66
Economic Profit
Residual Income $10.93 $12.29 $16.28 68
ROIC Compounder $9.13 $12.91 $20.25 67
Growth Earnings
Growth-Adj P/E $16.58 $23.69 $30.79 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 49
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 37
Distance to the 52-week high, does not count
New shares 36
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $170,750, on Jun 5, 2026. Over the same period, one person sold shares worth $3.7M.

  • SaleGIC Private Ltd10% owner3× since Aug 7, 2026: 29,085,901 shares, avg. $34.98$1.0BOct 8, 2026
  • SaleHux Investment Pte. Ltd.10% owner2× since Aug 5, 2026: 3,848,612 shares, avg. $35.66$137.3MAug 14, 2026
  • SaleDouglas P GolwasChief Commercial Officer, 10% owner100,000 shares at $36.77$3.7MJun 16, 202610b5-1 plan
  • BuyJessi L CorcoranPrincipal Accounting Officer5,000 shares at $34.15$170,750Jun 5, 2026
  • SaleBX Mozart ML-2 Holdco GP L.L.C.10% owner33,317,824 shares at $36.54$1.2BMay 28, 2026
  • SaleBCP 8 Holdings Mozart Manager L.L.C.10% owner33,317,824 shares at $36.54$1.2BMay 28, 2026
  • SaleMend Partners II, L.P.10% owner31,868,237 shares at $36.54$1.2BMay 28, 2026
  • SaleMozart Aggregator II UNLV Holdco L.P.10% owner27,852,986 shares at $40.51$1.1BMar 10, 2026
  • SaleBlackstone Group Management L.L.C.10% owner27,852,986 shares at $40.51$1.1BMar 10, 2026
  • SaleHFCP X (Parallel-A), L.P.10% owner2× since Dec 18, 2025: 32,219,608 shares, avg. $38.22$1.2BMar 10, 2026

Plus 11 more entries from the last 12 months.

Plus 19 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +68.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+68.7%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 8%
⚠ Approximate: the rate leans on 2025, which sits 57% above its own trend.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +15.7% a year for the price and +4.9% for the forecasts.
Forecast 2026 (sales)+9.8%
Forecast 2027 (sales)+7.8%
Projected 2028 (sales)+7.1%
Projected 2029 (sales)+6.4%
Projected 2030 (sales)+5.7%

MDLN screens overvalued: fair value 28% below the price. Compare with Intuitive Surgical, Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.
Note from the team Oct 11, 2026
AI conclusion: Prime Vendor agreements deliver bundled revenue from hospitals and care facilities, yet limited signals leave doubts about sustaining growth in a competitive medical supplies market.
Main risk: Rivals such as McKesson and Cardinal Health could win Prime Vendor agreements or offer lower prices through scale and different models, squeezing Medline's margins on bundled supply chain services and products.
Bull case: Medline could leverage its vertical integration and Mpower AI platform to deepen Prime Vendor relationships and convert more customers to higher-margin branded products faster than rivals.
Bear case: If rivals capture key contracts and regulatory issues lead to sustained recalls or lost GPO access, Medline could see declining volumes in its core bundled offerings and higher costs that pressure the entire model.
Medline secures much of its revenue through Prime Vendor agreements that bundle products with supply chain services for hospitals and care facilities. Major 10% owners recently sold over 20 million shares in early October just before the November earnings release. Does this pattern reflect routine portfolio moves, or does it point to deeper questions about sustaining growth in a competitive medical supplies market?
Join the discussion →

Compare Medline Inc. Class A Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −28.0% · Below median
Profitability
Return on equity (12 months) 4.9% · Below median
Return on assets 3.0% · Below median
Net margin (12 months) 2.3% · Below median
Operating margin (12 months) 0.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 11.6% · Above median
Balance sheet
Debt / equity 1.16× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 91.7× · Priciest 25%
P/B 5.06× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.81× · Cheaper than median
Price / free cash flow (fiscal year) 41.9× · Priciest 25%
EV/EBITDA 25.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 22
FUTURE (revenue growth)58 · sector 40
PAST (return on equity)20 · sector 30
HEALTH (low debt)42 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $87.18 $131.06 +50% vs MDLN
EssilorLuxottica Société anonyme EL €191.95 €196.22 +2% vs MDLN
Intuitive Surgical, Inc ISRG $468.52 $353.90 −24% vs MDLN
Alcon Inc ALC CHF 62.78 CHF 33.91 −46% vs MDLN
Straumann Holding STMN CHF 105.85 CHF 45.50 −57% vs MDLN
Becton, Dickinson and Company BDX $213.55 $82.34 −61% vs MDLN
West Pharmaceutical Services, Inc WST $392.48 $139.22 −65% vs MDLN
Repligen Corporation RGEN $168.48 $43.94 −74% vs MDLN
Sartorius Stedim Biotech S.A DIM €224.20 €54.82 −76% vs MDLN
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs MDLN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medline Inc. Class A Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medline Inc. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/MDLN

Frequently asked questions

Is Medline Inc. Class A (MDLN) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $28.64 versus a price of $39.76, about 28% lower (overvalued).
What is the fair value of MDLN?
Our model-based fair value for Medline Inc. Class A Common Stock is $28.64 (as of Nov 5, 2026), built from audited fundamentals. The current price: $39.76.
What is the quality score of MDLN?
Medline Inc. Class A Common Stock has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medline Inc. Class A (MDLN)?
Our model-based price target is the fair value of $28.64 (as of Nov 5, 2026) from 22 valuation models. Cautious scenario $15.89, optimistic scenario $36.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Medline Inc. Class A Common Stock stock forecast for 2026?
Our models put fair value at $28.64, about 28% lower versus a price of $39.76 (overvalued). Cautious scenario $15.89, optimistic scenario $36.33. The calculation is refreshed regularly with new filings.
What is the revenue of Medline Inc. Class A (MDLN)?
Medline Inc. Class A Common Stock reported trailing-twelve-month revenue of about $29.9B (latest available figure, as of Nov 5, 2026).
What growth is priced into Medline Inc. Class A (MDLN)?
For today's price to be fair in a discounted-cash-flow model, Medline Inc. Class A Common Stock would have to grow free cash flow by +18.4 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +9.9 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of MDLN use?
Our models discount Medline Inc. Class A Common Stock at 9.2 %: a base by market capitalisation (large), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medline Inc. Class A Common Stock that is +18.4 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Medline Inc. Class A (MDLN) delivered so far?
Over the past 3 years revenue at Medline Inc. Class A Common Stock grew +9.9 % a year. The price currently implies +18.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medline Inc. Class A (MDLN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Medline Inc. Class A Common Stock (+18.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medline Inc. Class A (MDLN)?
The free-cash-flow yield on the price is 3.79 %: that much free cash flow Medline Inc. Class A Common Stock produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medline Inc. Class A (MDLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medline Inc. Class A Common Stock it is $28.64 per share (as of Nov 5, 2026), against a price of $39.76. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Medline Inc. Class A Common Stock stock overvalued or undervalued in 2026?
As of Nov 5, 2026, MDLN trades above its calculated fair value: price $39.76, fair value $28.64, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDLN?
No. The price is what the market pays today ($39.76); the fair value is what the company's own numbers justify ($28.64). For Medline Inc. Class A Common Stock the two are $11.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medline Inc. Class A Common Stock worth?
The market values Medline Inc. Class A Common Stock at about $54.3B (market capitalisation, as of Nov 5, 2026). Per share that is $39.76; our models calculate a fair value of $28.64 per share.
What do the bullish and bearish scenarios say about MDLN?
Our models span a range for Medline Inc. Class A Common Stock: cautious scenario $15.89, base $28.64, optimistic $36.33 per share (as of Nov 5, 2026, price $39.76). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MDLN?
Medline Inc. Class A Common Stock trades at a price-to-earnings ratio of 91.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $28.64 is built from several models across several years. Other multiples: P/B 5.1, P/S 1.8, EV/EBITDA 25.8.
How solid is the balance sheet of Medline Inc. Class A (MDLN)?
Balance-sheet figures for Medline Inc. Class A Common Stock (as of Nov 5, 2026): return on equity 4.9%, debt of 1.16 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
Which stocks are comparable to Medline Inc. Class A Common Stock?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Alcon Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medline Inc. Class A Common Stock stock attractive at the current price?
The data as of Nov 5, 2026: price $39.76, calculated fair value $28.64 (−28%), Quality Score 50/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDLN calculated?
We run Medline Inc. Class A Common Stock through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $28.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Medline Inc. Class A Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medline Inc. Class A (MDLN)?
The closing price on Nov 5, 2026 was $39.76. Our model-based fair value is $28.64, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medline Inc. Class A Common Stock right now?
The price sits above even our optimistic bull case ($36.33). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($15.89 to $36.33) leaves room in how you read the outcome.

Key figures of Medline Inc. Class A Common Stock

How large is the market capitalisation of Medline Inc. Class A (MDLN)?
The market capitalisation of Medline Inc. Class A Common Stock is $54.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medline Inc. Class A (MDLN)?
The price-to-sales ratio of Medline Inc. Class A Common Stock is 1.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medline Inc. Class A (MDLN)?
Earnings per share at Medline Inc. Class A Common Stock are $0.4400 (price ÷ EPS = P/E 91.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medline Inc. Class A (MDLN)?
The net margin of Medline Inc. Class A Common Stock is 2.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medline Inc. Class A (MDLN)?
The return on equity (ROE) of Medline Inc. Class A Common Stock is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medline Inc. Class A (MDLN)?
On an EBIT basis the return on assets of Medline Inc. Class A Common Stock is 5.3% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medline Inc. Class A (MDLN)?
The operating margin of Medline Inc. Class A Common Stock is 0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medline Inc. Class A (MDLN)?
Revenue at Medline Inc. Class A Common Stock is growing +11.6% versus a year earlier (3y avg +9.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medline Inc. Class A (MDLN)?
Earnings per share at Medline Inc. Class A Common Stock are growing +262% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medline Inc. Class A (MDLN) carry?
The net debt of Medline Inc. Class A Common Stock is $10.6B (fiscal year 2025, ≈ 8.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medline Inc. Class A Common Stock in the live analysis

One click puts Medline Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.